Menu

Salk Institute Suspends Cancer Scientist Inder Verma

The prominent researcher has been put on administrative leave pending an investigation into unspecified allegations.

Apr 23, 2018
Ashley Yeager

FLICKR, ALFRED ESSAInder Verma, a cancer and gene therapy scientist at the Salk Institute for Biological Studies in La Jolla, CA, has been placed on administrative leave, the San Diego Union-Tribune reported Saturday (April 21). The institute has hired The Rose Group, a San Diego–based international employment law and consulting firm, to investigate allegations, not yet made public, that were reported to the institute in February.

Dan Lewis, chairman of Salk’s board of trustees, emailed the institute’s staff members late last week to inform them that a formal investigation is underway and that “effective immediately, Dr. Verma has been placed on administrative leave, pending the outcome of the investigation. He will not be performing scientific or administrative roles on behalf of the Institute during this period.”

Complaints against Verma led to his suspension as editor-in-chief of the Proceedings of the National Academy of Sciences in December.

See “PNAS Editor-in-Chief Placed on Leave

In response to questions from Science about sexual harassment allegations, Verma responded through his lawyer in a statement: “I have never used my position at the Salk Institute to take advantage of others. I have also never engaged in any sort of intimate relationship with anyone affiliated with the Salk Institute.”

Likewise, Verma tells the San Diego Union-Tribune, “I believe that it is inappropriate for an individual in a position of authority to engage in any intimate relationship with a direct report or to use that position of authority to take advantage of others.”

As a leader at the Salk, Verma was directly criticized for making it difficult for women to succeed, according to a lawsuit filed against the institute by Vicki Lundblad in 2017. Two other Salk scientists, Katherine Jones and Beverly Emerson, also filed suits last year claiming that the institute “systemically discriminates against women in terms of salary, promotions and opportunities to compete for large private donations,” the Union-Tribune reports.

Salk’s first female president, Elizabeth Blackburn, announced she would leave the institute, the same week as Verma’s suspension from PNAS.

According to an email from Lewis to Science, the board of directors of the Salk Institute has asked that Fred “Rusty” Gage, who has served as interim president since Blackburn’s departure, continue in his role while the search for a new permanent president is placed on hold. Gage has agreed to stay in the leadership position.

January 2019

Cannabis on Board

Research suggests ill effects of cannabinoids in the womb

Marketplace

Sponsored Product Updates

WIN a VIAFLO 96/384 to supercharge your microplate pipetting!
WIN a VIAFLO 96/384 to supercharge your microplate pipetting!
INTEGRA Biosciences is offering labs the chance to win a VIAFLO 96/384 pipette. Designed to simplify plate replication, plate reformatting or reservoir-to-plate transfers, the VIAFLO 96/384 allows labs without the space or budget for an expensive pipetting robot to increase the speed and throughput of routine tasks.
FORMULATRIX® digital PCR technology to be acquired by QIAGEN
FORMULATRIX® digital PCR technology to be acquired by QIAGEN
FORMULATRIX has announced that their digital PCR assets, including the CONSTELLATION® series of instruments, is being acquired by QIAGEN N.V. (NYSE: QGEN, Frankfurt Stock Exchange: QIA) for up to $260 million ($125 million upfront payment and $135 million of milestones).  QIAGEN has announced plans for a global launch in 2020 of a new series of digital PCR platforms that utilize the advanced dPCR technology developed by FORMULATRIX combined with QIAGEN’s expertise in assay development and automation.
Application of CRISPR/Cas to the Generation of Genetically Engineered Mice
Application of CRISPR/Cas to the Generation of Genetically Engineered Mice
With this application note from Taconic, learn about the power that the CRISPR/Cas system has to revolutionize the field of custom mouse model generation!
Translational Models of Obesity, Dysmetabolism, Diabetes, and Complications
Translational Models of Obesity, Dysmetabolism, Diabetes, and Complications
This webinar, from Crown Bioscience, presents a unique continuum of translational dysmetabolic platforms that more closely mimic human disease. Learn about using next-generation rodent and spontaneously diabetic non-human primate models to accurately model human-relevant disease progression and complications related to obesity and diabetes here!